Tetramed Biotek Profile
Key Indicators
- Authorised Capital ₹ 6.50 M
as on 17-12-2024
- Paid Up Capital ₹ 6.50 M
as on 17-12-2024
- Company Age 22 Year, 6 Days
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.12 Cr
as on 17-12-2024
- Revenue 20.94%
(FY 2019)
- Profit -127.35%
(FY 2019)
- Ebitda -17.50%
(FY 2019)
- Net Worth -8.09%
(FY 2019)
- Total Assets 9.31%
(FY 2019)
About Tetramed Biotek
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 6.50 M and a paid-up capital of Rs 6.50 M.
The company currently has active open charges totaling ₹1.12 Cr.
Sushil Ghai and Parichit Ghai serve as directors at the Company.
- CIN/LLPIN
U24233PN2002PTC017518
- Company No.
017518
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Dec 2002
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Tetramed Biotek Private Limited offer?
Tetramed Biotek Private Limited offers a wide range of products and services, including Hair Care, Hair Growth for Men, Health Conditions, Pain Relief.
Who are the key members and board of directors at Tetramed Biotek?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parichit Ghai  | Whole-Time Director | 27-Jan-2017 | Current |
| Sushil Ghai | Director | 18-Dec-2002 | Current |
Financial Performance of Tetramed Biotek.
Tetramed Biotek Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 20.94% increase. The company also saw a substantial fall in profitability, with a 127.35% decrease in profit. The company's net worth dipped by a decrease of 8.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tetramed Biotek?
In 2019, Tetramed Biotek had a promoter holding of 94.06% and a public holding of 5.94%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 06 Apr 2023 | ₹1.00 M | Open |
Bank Of India Creation Date: 15 Jun 2006 | ₹1.00 Cr | Open |
Bank Of India Creation Date: 28 Jul 2004 | ₹0.20 M | Open |
How Many Employees Work at Tetramed Biotek?
Tetramed Biotek has a workforce of 2 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tetramed Biotek, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tetramed Biotek's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
